These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23999955)

  • 21. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST; Rey K; He J; Flanagan J; Fish BJ; Rogers ZR; Wang WC; Ware RE;
    Pediatr Blood Cancer; 2012 Jul; 59(1):170-2. PubMed ID: 21744485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
    Thompson BW; Miller ST; Rogers ZR; Rees RC; Ware RE; Waclawiw MA; Iyer RV; Casella JF; Luchtman-Jones L; Rana S; Thornburg CD; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik S; Howard TH; Luck L; Wang WC
    Pediatr Blood Cancer; 2010 Feb; 54(2):250-5. PubMed ID: 19731330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
    Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
    BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
    Lanzkron S; Haywood C; Fagan PJ; Rand CS
    J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
    Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E
    Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.
    Okam MM; Shaykevich S; Ebert BL; Zaslavsky AM; Ayanian JZ
    Med Care; 2014 Jul; 52(7):612-8. PubMed ID: 24926708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.
    Reeves SL; Dombkowski KJ; Peng HK; Phan H; Kolenic G; Creary SE; Madden B; Lisabeth LD
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30332. PubMed ID: 37046404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E; Tibalinda P; Sterzi E; Leufkens HMG; Makani J; Kaale E; Luzzatto L
    Am J Hematol; 2021 Jan; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract]   [Full Text] [Related]  

  • 38. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
    Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.
    Hankins JS; Penkert RR; Lavoie P; Tang L; Sun Y; Hurwitz JL
    Exp Biol Med (Maywood); 2016 Apr; 241(7):749-54. PubMed ID: 26940953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
    J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.